

Manfredi Rizzo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6964813/manfredi-rizzo-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274
papers

8,616
citations

52
h-index

79
g-index

327
ext. papers

10,549
ext. citations

4.2
avg. IF

6.2
L-index

#	Paper	IF	Citations
274	Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study.. <i>Healthcare (Switzerland)</i> , 2022 , 10,	3.4	6
273	The Role of Fructose as a Cardiovascular Risk Factor: An Update.. <i>Metabolites</i> , 2022 , 12,	5.6	8
272	Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	1
271	A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.. <i>Metabolites</i> , 2022 , 12,	5.6	3
270	The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update.. <i>Metabolites</i> , 2022 , 12,	5.6	1
269	Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	5
268	Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.. <i>Diabetes Therapy</i> , 2022 , 13, 453	3.6	4
267	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).. <i>Diabetes Therapy</i> , 2022 , 13, 795	3.6	1
266	The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022 , 15, 1023-1030	3.4	1
265	A New Comorbidity in Periodontitis: and Colorectal Cancer.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	1
264	Managing the Systemic Impact of Periodontitis. <i>Medicina (Lithuania)</i> , 2022 , 58, 621	3.1	2
263	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.. <i>Advances in Therapy</i> , 2022 , 39, 2452-2467	4.1	4
262	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 787761	5.4	13
261	The Role of Endothelium in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
260	Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?. <i>Endocrine</i> , 2021 , 1	4	0
259	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 21, 90	2.1	3
258	Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. <i>Diabetes Therapy</i> , 2021 , 12, 3037-3054	3.6	5

257	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. <i>Biomedicines</i> , 2021 , 9,	4.8	4
256	Nutraceuticals and Lipid Management. <i>Contemporary Cardiology</i> , 2021 , 173-189	0.1	1
255	Long-Term Brain Disorders in Post Covid-19 Neurological Syndrome (PCNS) Patient. <i>Brain Sciences</i> , 2021 , 11,	3.4	16
254	Novel Therapeutical Approaches to Managing Atherosclerotic Risk. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
253	Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action. <i>International Journal of Cardiology</i> , 2021 , 329, 205-207	3.2	7
252	Preliminary Results of CitraVes Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study. <i>Metabolites</i> , 2021 , 11,	5.6	7
251	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2021 , 27, 3729-3740	3.3	1
250	Statin intolerance: new data and further options for treatment. <i>Current Opinion in Cardiology</i> , 2021 , 36, 487-493	2.1	5
249	New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?. <i>Diabetes Therapy</i> , 2021 , 12, 1605-1611	3.6	5
248	Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	13
247	The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
246	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021 , 67, 40-52	8.5	14
245	Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3379	7.5	10
244	Gender differences in the battle against COVID-19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13666	2.9	13
243	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. <i>Diabetes Research and Clinical Practice</i> , 2021 , 172, 108535	7.4	5
242	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. <i>Diabetes Therapy</i> , 2021 , 12, 261-274	3.6	13
241	Nutraceuticals and Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2021 , 67-87	0.1	
240	Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4

239	Future Perspectives in Nutraceutical Research. <i>Contemporary Cardiology</i> , 2021 , 289-293	0.1	
238	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021 , 17, 856-863	2.9	7
237	Diabetes and COVID-19: A Tale of 2 Pandemics. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, e1-e2	3.1	2
236	The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1309-1315	4.1	2
235	Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 57	6	16
234	Exploring the Role of Skeletal Muscle in Insulin Resistance: Lessons from Cultured Cells to Animal Models. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
233	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021 , 1867, 166148	6.9	4
232	Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 178, 108935	7.4	0
231	Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-12	4.1	8
230	Metabolic Syndrome in Patients with Coexistent Obstructive Sleep Apnea Syndrome and Chronic Obstructive Pulmonary Disease (Overlap Syndrome). <i>Metabolic Syndrome and Related Disorders</i> , 2020 , 18, 296-301	2.6	3
229	Efficacy of a fasting-mimicking diet in functional therapy for depression: A randomised controlled pilot trial. <i>Journal of Clinical Psychology</i> , 2020 , 76, 1807-1817	2.8	5
228	Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020 , 25, 494-496	2.6	18
227	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020 , 155, 104719	10.2	7
226	Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	18
225	An overview of statin-induced myopathy and perspectives for the future. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 601-615	4.1	18
224	Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. <i>Metabolic Syndrome and Related Disorders</i> , 2020 , 18, 173-175	2.6	51
223	COVID-19 and diabetes management: What should be considered?. <i>Diabetes Research and Clinical Practice</i> , 2020 , 163, 108151	7.4	63
222	Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. <i>Metabolites</i> , 2020 , 10,	5.6	5

221	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020 , 10,	5.6	9
220	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020 , 111, 1543-1548	12.7	18
219	Comparison of Reported Deaths From COVID-19 and Increase in Total Mortality in Italy. <i>JAMA Internal Medicine</i> , 2020 , 180, 1250-1252	11.5	10
218	NLRP3 Inflammasome Biomarker-Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. <i>Metabolites</i> , 2020 , 10,	5.6	10
217	Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. <i>European Journal of Integrative Medicine</i> , 2020 , 37, 101164	1.7	1
216	Safety Evaluation of Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. <i>Antioxidants</i> , 2020 , 9,	7.1	16
215	Pasta Supplemented with Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020 , 10,	5.6	8
214	The Consumption of Fast Food Favors Weight Increase in Young Hellenic Navy Personnel: A 10-Year Follow-Up Study. <i>Metabolic Syndrome and Related Disorders</i> , 2020 , 18, 493-497	2.6	
213	Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. <i>Scientific Reports</i> , 2020 , 10, 21613	4.9	25
212	A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. <i>Oncotarget</i> , 2019 , 10, 1284-1305	3.3	7
211	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019 , 143, 1-16	10.2	54
210	Advances in pharmacological treatment of type 1 diabetes during pregnancy. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 983-989	4	
209	Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. <i>Diabetes Research and Clinical Practice</i> , 2019 , 149, 163-169	7.4	16
208	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019 , 115, 204-212	9.9	25
207	Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2038-2050	3.3	10
206	Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3704-3714	3.3	6
205	Altlix Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019 , 11,	6.7	21
204	Future perspectives of the pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 129-143	3.8	12

203	Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. <i>Phytotherapy Research</i> , 2019 , 33, 862-870	6.7	24
202	Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 476-484	6.9	15
201	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. <i>Acta Diabetologica</i> , 2019 , 56, 289-299	3.9	8
200	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. <i>Critical Reviews in Food Science and Nutrition</i> , 2019 , 59, 328-335	11.5	9
199	Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials 2019 , 33, 862		1
198	Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2018 , 16, 190-196	2.6	10
197	Serum lipoproteins are not associated with the severity of asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 50, 57-61	3.5	3
196	Management of Statin Intolerance in 2018: Still More Questions Than Answers. <i>American Journal of Cardiovascular Drugs</i> , 2018 , 18, 157-173	4	86
195	New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. <i>Current Opinion in Cardiology</i> , 2018 , 33, 444-454	2.1	3
194	Natural approaches in metabolic syndrome management. <i>Archives of Medical Science</i> , 2018 , 14, 422-441	2.9	83
193	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018 , 24, 239-258	3.3	54
192	Pharmacotherapy for gestational diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1407-1414	4	7
191	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 2814-2821	6.9	60
190	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 96-118	15.1	157
189	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017 , 68, 99-108	2.1	23
188	The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review. <i>Lipids in Health and Disease</i> , 2017 , 16, 35	4.4	5
187	Small, dense LDL: an update. <i>Current Opinion in Cardiology</i> , 2017 , 32, 454-459	2.1	18
186	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 972-985.e9	4.9	21

185	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017 , 77, 1187-1197	12.1	19
184	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017 , 75, 307-326	6.4	183
183	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017 , 75, 361-373	6.4	30
182	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017 , 75, 731-767	6.4	186
181	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017 , 13, 965-1005	2.9	173
180	NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. <i>Nutrients</i> , 2017 , 9,	6.7	39
179	GLP-1 receptor agonists, carotid atherosclerosis and retinopathy. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1163-1165	4	3
178	Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. <i>Advances in Therapy</i> , 2017 , 34, 1966-1975	4.1	18
177	Intensive LDL-cholesterol lowering therapy and neurocognitive function. <i>Pharmacology & Therapeutics</i> , 2017 , 170, 181-191	13.9	46
176	PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk. <i>Current Pharmaceutical Design</i> , 2017 , 23, 894-902	3.3	8
175	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2496-2503	3.3	30
174	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. <i>Clinical Endocrinology</i> , 2016 , 85, 694-695	3.4	1
173	Plasma heme oxygenase-1 is decreased in peripheral artery disease patients. <i>Molecular Medicine Reports</i> , 2016 , 14, 3459-63	2.9	17
172	Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea. <i>Angiology</i> , 2016 , 67, 937-944	2.1	2
171	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 1501-9	14.6	100
170	Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. <i>Atherosclerosis</i> , 2016 , 248, 62-75	3.1	28
169	Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress. <i>Angiology</i> , 2016 , 67, 945-950	2.1	37
168	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016 , 23, 1175-81	6.5	29

167	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016 , 103, 236-52	10.2	49
166	Anti-cytokine therapy for prevention of atherosclerosis. <i>Phytomedicine</i> , 2016 , 23, 1198-210	6.5	19
165	Incretins, Pregnancy, and Gestational Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2016 , 17, 597-602	2.6	11
164	PPAR in Cardiovascular Disorders. <i>PPAR Research</i> , 2016 , 2016, 6293629	4.3	5
163	IMPROVE-IT: what have we learned?. <i>Current Opinion in Cardiology</i> , 2016 , 31, 426-33	2.1	15
162	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. <i>Cardiovascular Diabetology</i> , 2016 , 15, 162	8.7	66
161	In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters. <i>Atherosclerosis</i> , 2016 , 251, 147-152	3.1	6
160	Effects of Armolipid Plus [®] on small dense LDL particles. <i>Clinical Lipidology</i> , 2016 , 11, 39-40		
159	Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2015 , 13, 319-28	2.6	20
158	Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015 , 99, 329-36	10.2	105
157	Oxidative stress markers at birth: Analyses of a neonatal population. <i>Acta Histochemica</i> , 2015 , 117, 486-91		11
156	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1391-7	5.4	26
155	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 576-82	4.9	42
154	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015 , 189, 47-55	3.2	110
153	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 935-55	4.1	94
152	High-Sensitivity C-Reactive Protein and Statin Initiation. <i>Angiology</i> , 2015 , 66, 503-7	2.1	
151	Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015 , 75, 382-9	2	8
150	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom? 2015 , 179-190		1

149	A Potential Link between Serum Low-Density Lipoproteins and Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 261-2	10.2	2
148	An evaluation of RVX-208 for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1389-98	5.9	25
147	Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015 , 178, 111-6	3.2	129
146	Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 603-6	5.6	59
145	Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan. <i>Angiology</i> , 2015 , 66, 416-21	2.1	29
144	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015 , 5, 9902	4.9	109
143	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015 , 11, 1-23	2.9	252
142	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015 , 14, 29	4.4	34
141	Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome. <i>Angiology</i> , 2015 , 66, 856-61	2.1	26
140	Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 24-34	6.4	139
139	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. <i>Frontiers in Pharmacology</i> , 2015 , 6, 299	5.6	65
138	Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis. <i>Cell Stress and Chaperones</i> , 2014 , 19, 343-53	4	43
137	Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. <i>Acta Diabetologica</i> , 2014 , 51, 625-32	3.9	27
136	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 353-68	6.5	48
135	Predictors of insulin resistance in patients with obesity: a pilot study. <i>Angiology</i> , 2014 , 65, 22-30	2.1	37
134	Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. <i>Metabolic Syndrome and Related Disorders</i> , 2014 , 12, 1-10	2.6	8
133	ETC-1002: a future option for lipid disorders?. <i>Atherosclerosis</i> , 2014 , 237, 705-10	3.1	33
132	Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers. <i>Journal of Periodontology</i> , 2014 , 85, 1408-15	4.6	18

131	Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. <i>Cardiovascular Diabetology</i> , 2014 , 13, 49	8.7	62
130	Periodontitis, blood lipids and lipoproteins. <i>Clinical Lipidology</i> , 2014 , 9, 261-276		1
129	Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. <i>PLoS ONE</i> , 2014 , 9, e91565	3.7	10
128	Gestational diabetes and the metabolic syndrome: can obesity and small, dense low density lipoproteins be key mediators of this association?. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 38-46 ^{2.6}		9
127	Novel anti-obesity drugs and plasma lipids. <i>Clinical Lipidology</i> , 2014 , 9, 179-187		7
126	Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. <i>Angiology</i> , 2014 , 65, 538-42	2.1	31
125	New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. <i>Angiology</i> , 2014 , 65, 333-42	2.1	30
124	High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study. <i>Journal of Cardiovascular Medicine</i> , 2014 , 15, 696-701	1.9	16
123	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 453-61 ^{6.5}		54
122	Prevalence of dyslipidemia and associated risk factors in Turkish adults. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 206-16	4.9	64
121	Association between COX-2 rs 6681231 genotype and interleukin-6 in periodontal connective tissue. A pilot study. <i>PLoS ONE</i> , 2014 , 9, e87023	3.7	11
120	Subfractions and subpopulations of HDL: an update. <i>Current Medicinal Chemistry</i> , 2014 , 21, 2881-91	4.3	63
119	Statins and new-onset diabetes. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3657-64	3.3	24
118	Incretin-based therapies, glucometabolic health and endovascular inflammation. <i>Current Pharmaceutical Design</i> , 2014 , 20, 4953-60	3.3	22
117	Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2014 , 20, 4961-9	3.3	56
116	The metabolic syndrome and HIV infection. <i>Current Pharmaceutical Design</i> , 2014 , 20, 4975-5003	3.3	15
115	LDL and HDL subfractions, dysfunctional HDL: treatment options. <i>Current Pharmaceutical Design</i> , 2014 , 20, 6249-55	3.3	14
114	Uric acid metabolism in pre-hypertension and the metabolic syndrome. <i>Current Vascular Pharmacology</i> , 2014 , 12, 572-85	3.3	12

113	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. <i>Lipids in Health and Disease</i> , 2013 , 12, 47	4.4	20
112	Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. <i>Clinical Biochemistry</i> , 2013 , 46, 1526-31	3.5	5
111	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013 , 168, 5437-47	3.2	53
110	Serum low density lipoprotein subclasses in asthma. <i>Respiratory Medicine</i> , 2013 , 107, 1866-72	4.6	26
109	PCSK9 inhibition - a novel mechanism to treat lipid disorders?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3869-77	3.3	38
108	Rational for statin use in psoriatic patients. <i>Archives of Dermatological Research</i> , 2013 , 305, 467-72	3.3	15
107	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013 , 72, 35-44	10.2	76
106	Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?. <i>Clinical Lipidology</i> , 2013 , 8, 273-277		2
105	Effects of obesity and estradiol on Na ⁺ /K ⁺ -ATPase and their relevance to cardiovascular diseases. <i>Journal of Endocrinology</i> , 2013 , 218, R13-23	4.7	18
104	The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. <i>Clinical Lipidology</i> , 2013 , 8, 173-181		14
103	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013 , 29, 435-51	2.5	29
102	Clinical review: Association between metabolic syndrome and periodontitis: a systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 913-20	5.6	143
101	Smoking and small, dense low-density lipoproteins. <i>Angiology</i> , 2013 , 64, 563	2.1	
100	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 698-707	4.6	11
99	Postprandial metabolism: from research to clinical practice. <i>Clinical Lipidology</i> , 2013 , 8, 395-398		
98	Mipomersen: a lipid-lowering agent with a novel mechanism of action. <i>Clinical Lipidology</i> , 2013 , 8, 279-282		1
97	Statin treatment in the elderly: how much do we know?. <i>Archives of Medical Science</i> , 2013 , 9, 585-8	2.9	8
96	The role of fibrate treatment in dyslipidemia: an overview. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3124-31	3.3	82

95	Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. <i>Nutrients</i> , 2013 , 5, 928-48	6.7	92
94	A review of the cardiovascular and anti-atherogenic effects of ghrelin. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4953-63	3.3	18
93	Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3858-68	3.3	34
92	Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012 , 8, 598-600	2.9	16
91	The effects of statins on blood pressure: current knowledge and future perspectives. <i>Archives of Medical Science</i> , 2012 , 8, 1-3	2.9	9
90	Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study. <i>Cell Stress and Chaperones</i> , 2012 , 17, 399-407	4	36
89	Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. <i>Clinical Endocrinology</i> , 2012 , 76, 177-8	3.4	7
88	Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea. <i>Angiology</i> , 2012 , 63, 617-21	2.1	16
87	The role of macrophage colony-stimulating factor in patients with acute myocardial infarction: a pilot study. <i>Angiology</i> , 2012 , 63, 127-30	2.1	1
86	High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. <i>Respiration</i> , 2012 , 83, 383-90	3.7	19
85	The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly. <i>Angiology</i> , 2012 , 63, 492-4	2.1	3
84	Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2012 , 7, 415-417	4.1	3
83	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 647-55	4	24
82	Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. <i>Translational Research</i> , 2011 , 157, 285-92	11	58
81	Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2011 , 95, 1073-9.e1-11	4.8	222
80	Heat shock protein-60 and risk for cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3662-3	3.3	28
79	Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. <i>Archives of Medical Science</i> , 2011 , 7, 5-7	2.9	15
78	Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011 , 19, 552-61	1.9	28

77	Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). <i>Current Pharmaceutical Design</i> , 2011 , 17, 3656-61	3.3	13
76	Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3699-712	3.3	14
75	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , 2011 , 9, 531-2	3.3	91
74	Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. <i>Clinical Lipidology</i> , 2011 , 6, 539-547		1
73	Recent insights into the relationship between inflammatory liver diseases and atherosclerosis. <i>Journal of Investigative Medicine</i> , 2011 , 59, 904-11	2.9	12
72	New lipid modulating drugs: the role of microsomal transport protein inhibitors. <i>Current Pharmaceutical Design</i> , 2011 , 17, 943-9	3.3	24
71	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , 2011 , 9, 533-71	3.3	138
70	Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. <i>Angiology</i> , 2010 , 61, 584-90	2.1	15
69	Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. <i>European Heart Journal</i> , 2010 , 31, 1633-9	9.5	57
68	Is diabetes the cost to pay for a greater cardiovascular prevention?. <i>International Journal of Cardiology</i> , 2010 , 144, 309-10	3.2	4
67	An update on the relationships between rheumatoid arthritis and atherosclerosis. <i>Atherosclerosis</i> , 2010 , 212, 377-82	3.1	41
66	An update on the role of markers of inflammation in atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010 , 17, 1-11	4	149
65	Ethnic differences in serum lipoproteins and their determinants in South African women. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 1341-50	12.7	53
64	Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. <i>IDrugs: the Investigational Drugs Journal</i> , 2010 , 13, 103-11		5
63	Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. <i>Human Reproduction</i> , 2009 , 24, 2286-92	5.7	64
62	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. <i>Acta Diabetologica</i> , 2009 , 46, 1-11	3.9	22
61	Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. <i>Clinical Endocrinology</i> , 2009 , 70, 870-5	3.4	78
60	Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. <i>International Journal of Clinical Practice</i> , 2009 , 63, 56-62	2.9	63

59	Long-term consequences of polycystic ovary syndrome on cardiovascular risk. <i>Fertility and Sterility</i> , 2009 , 91, 1563-7	4.8	44
58	The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. <i>Clinica Chimica Acta</i> , 2009 , 406, 36-40	6.2	14
57	LDL size and subclasses in patients with abdominal aortic aneurysm. <i>International Journal of Cardiology</i> , 2009 , 134, 406-8	3.2	25
56	Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009 , 123, 1103-10, 1110.e1-4	11.5	119
55	Atherogenic dyslipidemia and oxidative stress: a new look. <i>Translational Research</i> , 2009 , 153, 217-23	11	78
54	The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?. <i>Atherosclerosis</i> , 2009 , 204, 330-3	3.1	27
53	Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. <i>Atherosclerosis</i> , 2009 , 207, 502-6	3.1	50
52	Therapy with noninvasive ventilation in patients with obstructive sleep apnoea: effects on atherogenic lipoprotein phenotype. <i>Medical Hypotheses</i> , 2009 , 73, 441-4	3.8	4
51	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1495-503	5.9	62
50	Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. <i>Coronary Artery Disease</i> , 2009 , 20, 15-20	1.4	28
49	When Periods Stop: Long-Term Consequences of PCOS 2009 , 265-270		
48	Should we routinely measure low-density and high-density lipoprotein subclasses?. <i>Clinical Laboratory</i> , 2009 , 55, 421-9	2	23
47	Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. <i>Diabetic Medicine</i> , 2008 , 25, 1406-11	3.5	58
46	Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. <i>Growth Hormone and IGF Research</i> , 2008 , 18, 264-6	2	4
45	Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2008 , 197, 237-41	3.1	50
44	Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. <i>Atherosclerosis</i> , 2008 , 200, 389-95	3.1	33
43	The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2295-303	4	13
42	Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 343-9	4	47

41	Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: the role of C-reactive protein. <i>Journal of Investigative Medicine</i> , 2008 , 56, 32-40	2.9	16
40	Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. <i>Coronary Artery Disease</i> , 2008 , 19, 139-44	1.4	51
39	Editorial [Inflammation and Atherosclerosis: Recent Insights and Future Perspectives]. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2008 , 7, 150-151	2	1
38	Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions. <i>Menopause</i> , 2008 , 15, 240-7	2.5	13
37	Recent insights on dark chocolate consumption and cardiovascular risk. <i>Southern Medical Journal</i> , 2008 , 101, 1194	0.6	
36	Fever of unknown origin in a Mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991-2002). <i>Internal and Emergency Medicine</i> , 2008 , 3, 219-25	3.7	16
35	How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?. <i>American Journal of Obstetrics and Gynecology</i> , 2008 , 198, 28.e1-5	6.4	20
34	Do We Need Better Lipid Tools for Cardiovascular Risk Assessment?. <i>Southern Medical Journal</i> , 2008 , 101, 221	0.6	
33	Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 1362-7	7	13
32	Small, dense low-density-lipoproteins and the metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 14-20	7.5	48
31	Who needs to care about small, dense low-density lipoproteins?. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1949-56	2.9	41
30	Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. <i>Advances in Therapy</i> , 2007 , 24, 575-82	4.1	19
29	Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 186-9	5.6	95
28	The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007 , 115, 477-82	2.3	28
27	Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. <i>Future Cardiology</i> , 2007 , 3, 553-8	1.3	1
26	The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1103-11	2.5	32
25	Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. <i>European Journal of Endocrinology</i> , 2007 , 156, 361-7	6.5	23
24	Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. <i>Archives of Medical Research</i> , 2006 , 37, 1004-9	6.6	32

23	Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. <i>Stroke</i> , 2006 , 37, 482-6	6.7	92
22	Low-density lipoprotein size and cardiovascular risk assessment. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006 , 99, 1-14	2.7	186
21	Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 662-8	12.7	15
20	Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 1308-16	12.7	13
19	Low-density lipoprotein size and cardiovascular prevention. <i>European Journal of Internal Medicine</i> , 2006 , 17, 77-80	3.9	14
18	Statins, fracture risk, and bone remodeling: What is true?. <i>American Journal of the Medical Sciences</i> , 2006 , 332, 55-60	2.2	15
17	The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis. <i>Vascular Disease Prevention</i> , 2006 , 3, 269-274		2
16	The clinical relevance of low-density-lipoproteins size modulation by statins. <i>Cardiovascular Drugs and Therapy</i> , 2006 , 20, 205-17	3.9	51
15	Effect of statins on low-density lipoprotein size: a new role in cardiovascular prevention?. <i>Southern Medical Journal</i> , 2006 , 99, 1015-6	0.6	2
14	Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. <i>International Journal of Cardiology</i> , 2005 , 101, 213-7	3.2	24
13	Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005 , 15, 361-7	4.5	8
12	Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. <i>American Journal of Cardiology</i> , 2005 , 96, 1266-72	3	35
11	Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005 , 12, 237-9	4	55
10	A case of bowel schistosomiasis not adhering to endoscopic findings. <i>World Journal of Gastroenterology</i> , 2005 , 11, 7044-7	5.6	8
9	Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. <i>European Journal of Endocrinology</i> , 2004 , 150, 831-6	6.5	
8	Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 141-6	9.4	30
7	Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. <i>Metabolism: Clinical and Experimental</i> , 2004 , 53, 483-7	12.7	11
6	Low-density-lipoprotein peak particle size in a Mediterranean population. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 126-33	4.6	32

5	Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. <i>Clinica Chimica Acta</i> , 2003 , 328, 91-7	6.2	1
4	Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002 , 89, 460-2	3	14
3	Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. <i>American Journal of Medicine</i> , 2001 , 110, 103-10	2.4	120
2	Overexpression of human hepatic lipase and ApoE in transgenic rabbits attenuates response to dietary cholesterol and alters lipoprotein subclass distributions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 625-32	9.4	31
1	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> ,	10.3	3